Summanr Carboplatin. a cisplatinum analogue, has no reported nephrotoxicity in phase I'II studies, assessed by creatinine clearance. We prospectively deterniined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400mgm 2 day 1 and vincristine 2mg day 1 al., 1985). An alternative approach was the synthesis of analogues of cisplatin with the aim to find Pt-complexes with less nephrotoxicity and more or comparable antitumour activity (Burchenal et al., 1979) . About 2,000 second generation Pt-compounds have been synthesised and screened for cytotoxicity. Only a few have been selected for clinical evaluation, of which carboplatin (CBDCA, JM8) probably is the most promising. In human and animal studies carboplatin has demonstrated increased haematological toxicity compared to CDDP, but it is less emetogenic and has little or no oto-or neurotoxicity and no nephrotoxicity even in the absence of forced diuresis (Lelieveld et al.. 1984 : Van Glabbeke et al., 1988 . In these studies the renal function was measured by monitoring serum creatinine and creatinine clearances. However, the determination of creatinine as a reflection of the glomerular filtration rate has proved to be a relatively insensitive method to monitor CDDP-induced renal damage (Meijer et al., 1983; Daugaard et al., 1988) . Moreover, using 52Cr EDTA clearances, Calvert et al. (1982) were also unable to identify CBDCA as a nephrotoxic drug.
The introduction of cisplatin (CDDP) in the early seventies resulted in a major step forward in anticancer chemotherapy (Carter et al., 1984) . However. cisplatin has a narrow therapeutic index especially in regard to nephrotoxicity, limiting the clinical utility of this agent (Madias & Harrington. 1978) . Several ways have been employed to overcome this problem. Although therapeutic index of CDDP has improved with the use of such manoeuvres, the drug does remain nephrotoxic (Al-Sarraf et al., 1983; Ozols et al.. 1984; Markham et al., 1985; Bodenner et al., 1986; Elfenrnk et al., 1986; Offerman et al., 1985) . An alternative approach was the synthesis of analogues of cisplatin with the aim to find Pt-complexes with less nephrotoxicity and more or comparable antitumour activity (Burchenal et al., 1979) . About 2,000 second generation Pt-compounds have been synthesised and screened for cytotoxicity. Only a few have been selected for clinical evaluation, of which carboplatin (CBDCA, JM8) probably is the most promising. In human and animal studies carboplatin has demonstrated increased haematological toxicity compared to CDDP, but it is less emetogenic and has little or no oto-or neurotoxicity and no nephrotoxicity even in the absence of forced diuresis (Lelieveld et al.. 1984 : Van Glabbeke et al., 1988 . In these studies the renal function was measured by monitoring serum creatinine and creatinine clearances. However, the determination of creatinine as a reflection of the glomerular filtration rate has proved to be a relatively insensitive method to monitor CDDP-induced renal damage (Meijer et al., 1983; Daugaard et al., 1988) . Moreover, using 52Cr EDTA clearances, Calvert et al. (1982) were also unable to identify CBDCA as a nephrotoxic drug.
In this study we prospectively determined changes in glomerular filtration rate and effective renal plasma flow by the more sensitive method developed by Donker et al. (1977) in 10 patients treated with standard dose carboplatin. The possible tubular damage was monitored by measuring the excretion of tubular enzymes.
Methods

Patients and therapy
Ten patients, one female, nine male, were studied. All had histologically proved lung cancer (eight small cell lung cancer, one squamous cell carcinoma, one endobronchial carcinoid All patients were treated with carboplatin 400mgm 2 day 1 and vincristine 2mg day 1 and 8 every 4 weeks. Carboplatin was dissolved in 250 ml of glucose 5% and given as a 30 mn i.v. infusion on day 1. Vincristine was given as bolus injection. No pre-or post-hydration was given.
Seven responding patients received the maximum of five courses. The treatment had to be stopped in two patients after three and in one patient after two courses. because of tumour progression.
Renal function studies Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured simultaneously in supine position with radioisotopes. ERPF was determined by measuring the clearance of 1311-hippuran (I x V P) and GFR by the clearance of '251-iothalamate (Ux V P) (I= counts per minute of I ml sustaining solution, V= infusion volume or urine volume in ml per minute, P =counts per minute in 2 ml of plasma and U=counts per minute in 2ml urine). After a standard pnrmary dose and sustaining infusion for 2h, 1-h clearances were determined for acute effects and 2-h clearances for cumulative effects. For the latter. values are the mean of two 2-h clearances, which were corrected for standard body surface area. Errors in GFR introduced by incomplete collection of urine were corrected to a method previously described. The day to day variation of GFR is 2O2% and of ERPF <5% (Donker et al., 1977) . Filtration fraction (FF) was calculated as the quotient of GFR and ERPF. Creatinine clearances were also corrected for incomplete collection of urine, using the same method as mentioned above.
These vanrables were studied before and during four hours after the first carboplatin infusion in order to determine acute effects on renal function. Cumulative effects were also measured during 4h 4 weeks after each course, just before the administration of the following courses, i.e. on days 29, 57, 85. 113 and 141. During renal function studies urine was collected hourly for the determination of creatinine, LDH, alkaline phosphatase (ALP), gamma-GT and #2-microglobulin. Serum (Von Hoff, 1987) . There have been sporadic observations of renal function deterioration after multiple courses of carboplatin (Calvert et al., 1982; Van Glabbeke et al., 1988; Rozenczweig et al., 1983; Leyvraz et al., 1985) . Also, the high dose (>800mgm-2) study of Gore et al. (1987) showed a fall in GFR of >25% in 55% of courses, as measured by (5"Cr) EDTA clearances.
Since vincristine has no reported nephrotoxicity (Schilsky, 1982; Weis & Poster, 1982) , we conclude from the data of our study that carboplatin has a cumulative dose related nephrotoxic effect, as there was no decrease in renal function parameters after the first course, but an impressive fall in GFR and ERPF after the second course, ultimately leading to a decrease of 38% after five courses in some patients. The fall in GFR may be clinically important because the degree of myelosuppression probably depends on GFR Fish et al., 1987; Egorin et al., 1985) . In our patients, however, we did not find cumulative haematological toxicity despite this decrease in GFR. Even the patient with a 38% reduction in GFR did not have severe myelosuppression.
This study also shows the superiority of the radiochemical preceding a similar change in GFR. Also, in experimental models of renal failure following intoxication with heavy metals, in the initial phase a reduction of renal blood flow can be found. In our study no such phenomenon could be found, as during the first course neither a fall in GFR nor in ERPF was seen. Since a simultaneous decrease in both GFR and ERPF occurred 4 weeks after course 2, we can only speculate, but not exclude, whether such a sequence of events did take place. Also, the intracellular presence of reactive Pt-compounds in the kidney is suggested to relate to this toxicity Stewart et al., 1985) . Therefore tubular damage might play an important role in Pt-induced nephrotoxicity. The reported renal uptake of carboplatin does not differ substantially from that for CDDP (Lelieveld et al., 1984; Owens et al., 1985) . CDDP induces tubular damage in most patients but we could not find signs of tubular damage after carboplatin administration as measured by the urinary excretion of tubular enzymes, because of infrequent sampling. For the evaluation of tubular damage timing of specimen collection plays an important role (Goren et al., 1987) . As reported for cisplatin (Goren et al., 1986) and carboplatin , urinary enzymes can peak as late as several days after the administration of the drug. Shillen et al. (1988) collected weekly specimens for the evaluation of excretion of urinary protein and enzymes in patients receiving multiple courses of carboplatin 400mg m .2 In some of their patients urinary enzymes peaked 2 weeks after the administration of the drug. Therefore, our results might be misleading in tha they were obtained for a period of only 4 h after administration.
We conclude from our data that carboplatin exerts doserelated cumulative renal damage. Careful monitoring, especially with regard to myelosuppression, in patients with impaired renal function or those pretreated with Pt containing regimens is therefore warranted. The observed reduction in renal function after carboplatin is in the same range compared to patients treated with cisplatin with saline diuresis (Meijer et al., 1983) . Although it has not been excluded that hyperhydration during carboplatin treatment could prevent the nephrotoxic effects, the value of administering this cytostatic drug on an outpatient base would disappear.
